2813-7868

Frontiers in Tuberculosis

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 71 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact71 DOIs
2

Add abstracts to 4 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact4 DOIs
3

Deposit reference lists for 1 record

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact1 DOIs

DOIs for this ISSN

Showing the top 5 of 71 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Ending tuberculosis: challenges and opportunities (10.3389/ftubr.2024.1487518)
ORCID
34.04 22
2 Innovative laboratory methods for improved tuberculosis diag… (10.3389/ftubr.2023.1295979)
ORCID
29.40 14
3 The role of the immune response in developing tuberculosis i… (10.3389/ftubr.2024.1438406)
ORCID
27.85 12
4 Tuberculosis meningitis coexisting with HIV Infection: a com… (10.3389/ftubr.2023.1242869)
ORCID
23.86 8
5 Mycobacterium abscessus pulmonary infection and associated r… (10.3389/ftubr.2024.1473341)
ORCID
22.58 7
6 Atg8ylation as a host-protective mechanism against Mycobacte… (10.3389/ftubr.2023.1275882)
ORCID
19.45 5
7 Bridging the gap: evaluating high TB burden country data nee… (10.3389/ftubr.2024.1384036)
ORCID
19.45 5
8 Test and treat approach for tuberculosis infection amongst h… (10.3389/ftubr.2024.1454277)
ORCID
19.45 5
9 Mycobacterial PE/PPE proteins function as “personal protecti… (10.3389/ftubr.2024.1458105)
ORCID
19.45 5
10 Predicting fitness in Mycobacterium tuberculosis with transc… (10.3389/ftubr.2025.1500899)
ORCID
19.45 5
11 Understanding the bacillary load and host interaction to des… (10.3389/ftubr.2023.1243479)
ORCID
17.47 4
12 Intersecting epidemics: deciphering the complexities of tube… (10.3389/ftubr.2024.1487793)
ORCID
17.47 4
13 Role of glutamine metabolism in tuberculosis pathogenesis: a… (10.3389/ftubr.2024.1432880)
ORCID
15.05 3
14 Editorial: Discerning active TB from latent infection (10.3389/ftubr.2025.1623373)
Abstract ORCID
15.05 1
15 Efficacy of RUTI® immunotherapy against active tuberculosis… (10.3389/ftubr.2023.1240684)
ORCID
11.93 2
16 Analyses of blood-derived host biomarkers for pulmonary tube… (10.3389/ftubr.2024.1377540)
ORCID
11.93 2
17 Discovery of a blood-based miRNA signature that can predict… (10.3389/ftubr.2024.1415346)
ORCID
11.93 2
18 Clinical and laboratory risk factors for pulmonary tuberculo… (10.3389/ftubr.2024.1433975)
ORCID
11.93 2
19 A broader evaluation of vaccine-induced T cell immunity agai… (10.3389/ftubr.2024.1435344)
ORCID
11.93 2
20 Coexistent anemia modulates systemic inflammation and exacer… (10.3389/ftubr.2024.1462654)
ORCID
11.93 2
21 Patterns of Mycobacterium tuberculosis genotypes and resista… (10.3389/ftubr.2025.1406536)
ORCID
11.93 2
22 Decoding the tuberculosis puzzle: mechanical factors driving… (10.3389/ftubr.2025.1570292)
ORCID
11.93 2
23 Predicting treatment adherence in patients with drug-resista… (10.3389/ftubr.2025.1659333)
ORCID
11.93 2
24 Acute phase proteins and IP-10 in plasma for tuberculosis di… (10.3389/ftubr.2023.1267221)
ORCID
7.53 1
25 Recognition and control of Mycobacterium tuberculosis-infect… (10.3389/ftubr.2023.1303505)
ORCID
7.53 1
26 Case report: Congenital multidrug-resistant tuberculosis (10.3389/ftubr.2024.1343217)
ORCID
7.53 1
27 Diverse interactions of Mycobacterium tuberculosis infection… (10.3389/ftubr.2024.1378068)
ORCID
7.53 1
28 Comorbidity profiles among sputum-positive tuberculosis pati… (10.3389/ftubr.2024.1433856)
ORCID
7.53 1
29 Serum-derived host miR-423-5p and miR-378a-3p as molecular m… (10.3389/ftubr.2024.1441258)
ORCID
7.53 1
30 Tissue-specific T cell profiles in Mycobacterium tuberculosi… (10.3389/ftubr.2025.1535945)
ORCID
7.53 1
31 Prevalence and risk factors of high blood pressure among per… (10.3389/ftubr.2025.1548843)
ORCID
7.53 1
32 Assessment of knowledge, attitudes, and practices regarding… (10.3389/ftubr.2025.1587839)
ORCID
7.53 1
33 Risk factors associated with multidrug-resistant pulmonary t… (10.3389/ftubr.2025.1608364)
ORCID
7.53 1
34 Mycobacteria as evolutionary drivers of host innate immunity… (10.3389/ftubr.2025.1735950)
ORCID
7.53 1
35 Acceptability and feasibility of oral swabs for tuberculosis… (10.3389/ftubr.2026.1726647)
ORCID
7.53 1
36 Advanced diagnostic methods for nontuberculous mycobacterial… (10.3389/ftubr.2026.1760581)
ORCID
7.53 1
37 Dose optimization of inhaled tigecycline in humans to overco… (10.3389/ftubr.2026.1762713)
ORCID
7.53 1
38 Tuberculosis: insights into latency, treatment strategies, a… (10.3389/ftubr.2023.1230713)
ORCID
0.00 0
39 Exposure of Mycobacterium tuberculosis to human alveolar lin… (10.3389/ftubr.2024.1352806)
ORCID
0.00 0
40 Mucosal BCG delivery provides a spectrum of protection from… (10.3389/ftubr.2024.1417939)
ORCID
0.00 0
41 iValiD-TB: a fully characterized Mycobacterium tuberculosis… (10.3389/ftubr.2024.1441923)
Abstract ORCID
0.00 0
42 Implications of serological, genomic, and epidemiological in… (10.3389/ftubr.2024.1484394)
ORCID
0.00 0
43 Novel diagnostic test for the detection of Mycobacterium tub… (10.3389/ftubr.2025.1536600)
ORCID
0.00 0
44 Targeted transcriptomic analyses of tuberculosis treatment r… (10.3389/ftubr.2025.1540194)
ORCID
0.00 0
45 The value of LAM and LprG in extracellular vesicles in the d… (10.3389/ftubr.2025.1608780)
ORCID
0.00 0
46 Trends and impact of government prevention policies on pulmo… (10.3389/ftubr.2025.1615486)
ORCID
0.00 0
47 Optimizing use of data and evidence-related tools to complem… (10.3389/ftubr.2025.1622167)
ORCID
0.00 0
48 Editorial: Rising stars in tuberculosis (10.3389/ftubr.2025.1635563)
Abstract References ORCID
0.00 0
49 Country-level heterogeneity in MDR-TB drug susceptibility su… (10.3389/ftubr.2025.1667354)
ORCID
0.00 0
50 A synthesis of youth activation initiatives and their impact… (10.3389/ftubr.2025.1668711)
ORCID
0.00 0